Radiotherapy

Proton Beam Therapy

European Oncology & Haematology, 2018;14(2):82–3 DOI: https://doi.org/10.17925/EOH.2018.14.2.82

Proton beam therapy is a type of radiotherapy that employs a high energy beam of protons rather than high energy X-rays to deliver a dose of radiotherapy for patients with cancer.1 The UK has been involved in the development of proton beam therapy; a specialist eye service at Clatterbridge, Merseyside, UK, was the first hospital-based […]

Radium-223 from bench to bedside: future directions for targeted alpha therapy – TAT 2017

Coverage of the Bayer supported satellite symposium “Radium-223 from bench to bedside and future directions for targeted alpha therapy ” at TAT 2017. The video has been published on the touchONCOLOGY website with permission from Bayer.

ESMO 2017 – Joe O’Sullivan Interview

Joe O’Sullivan discusses the role of radium-223 in the mestastatic prostate cancer treatment paradigm. Support: The filming of this video was supported by Bayer. Disclosures: Joe O’Sullivan has participated in Advisory Boards with Bayer, Sanofi and Janssen.

ECIO 2016: Bone cancer interventions

Percutaneous bone ablation, peripheral cementoplasty and percutaneous osteosynthesis are several of the palliative and, in some cases, curative techniques that interventional radiologists use today to combat bone metastases in cancer patients. Julien Garnon, Dimitrios Filippiadis and Frédéric Deschamps discuss the various treatment options, the research needed for these therapies to continue advancing and how other […]

ECIO 2016: Ablation of lung cancers

Thermal ablation is a valuable tool in the fight against lung cancers, offering a minimally invasive, reiterative treatment that is often suitable for patients who are deemed unfit for surgery or SBRT. Alice Gillams, Jens Ricke and Peter Kennedy discuss the advantages of the therapy, how it can be integrated into a multidisciplinary setting, and […]

ECIO 2016: A glimpse of the congress

Interventional radiologists from around the world, along with many of their oncologist colleagues, attended this year’s ECIO congress to learn more about advances in interventional oncology. Find out more about why they took part, and why they’ll be joining us again in Bilbao, Spain for ECIO 2017.

To Hyperfractionate or not to Hyperfractionate – Is it Really a Question?

European Oncology & Haematology, 2016;12(1):19–20 DOI: https://doi.org/10.17925/EOH.2016.12.01.19

The term hyperfractionated radiotherapy (HFR) is used when radiotherapy is delivered in doses below 1.8-2.0 Gy per fraction. The rationale for doing so can be found in the differences in intrinsic radiosensitivity between tumours and late responding normal tissues. A small dose per fraction will tend to increase the therapeutic ratio between tumour and critical […]

Comparison of coplanar and non-coplanar beam plans as treatment for prostate SBRT

Dr Linda Rossi – (Erasmus Medical Center, Rotterdam, Netherlands), talks to ecancertv at the 3rd ESTRO forum about her investigation into the comparison of coplanar and Non-coplanar beam plans as treatment for prostate stereotactic body radiotherapy (SBRT).

Radiation and immunology

Dr Weichselbaum talks to ecancertv at WIN 2015 about the therapeutic partnership being forged between radiotherapy and immunology.